Abstract
The capsid (CA) protein is the major structural component of HIV-1 and plays a key role in the regulation of viral life cycle. Inhibition of CA will affect the viral assembly and budding processes, causing decreased viral infectivity. This review describes the structure and function of the HIV-1 CA and latest progress in the discovery of HIV-1 CA inhibitors.
Keywords: HIV-1, AIDS, capsid inhibitor, antiviral agents, CA-N, CA-C, mutation
Mini-Reviews in Medicinal Chemistry
Title: Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors
Volume: 9 Issue: 4
Author(s): Jiyan Zhang, Xinyong Liu and Erik De Clercq
Affiliation:
Keywords: HIV-1, AIDS, capsid inhibitor, antiviral agents, CA-N, CA-C, mutation
Abstract: The capsid (CA) protein is the major structural component of HIV-1 and plays a key role in the regulation of viral life cycle. Inhibition of CA will affect the viral assembly and budding processes, causing decreased viral infectivity. This review describes the structure and function of the HIV-1 CA and latest progress in the discovery of HIV-1 CA inhibitors.
Export Options
About this article
Cite this article as:
Zhang Jiyan, Liu Xinyong and De Clercq Erik, Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors, Mini-Reviews in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/138955709787847958
DOI https://dx.doi.org/10.2174/138955709787847958 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused Heterocycles
Current Medicinal Chemistry DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews Biosafety of Herpesvirus Vectors
Current Gene Therapy EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Targeting miRNAs for Pancreatic Cancer Therapy
Current Pharmaceutical Design Glycoconjugates in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design